Navigation

Skiplink Navigation

Main Features

Infant drugs company struggles

The drugs company, Actelion, said on Thursday that its third quarter loss widened to SFr11.7 million ($6.6 million). Its losses for the same period in 1999 amounted to SFr3.5 million.

But the management said the figures were in line with expectations.

The company has yet to launch its first product. It expects to begin selling the hypertension drug, Tracleer, in the second half of next year pending approval from the United States Food and Drug Administration.

Actelion is listed on the high-tech SWX New Market and its management team is made up largely of former Roche employees.

swissinfo with agencies


Links

Neuer Inhalt

Horizontal Line


Survey Swiss Abroad

Survey: Keyboard and Hand close-up

Dear Swiss Abroad, tell us what you think

Survey Swiss Abroad

subscription form

Form for signing up for free newsletter.

Sign up for our free newsletters and get the top stories delivered to your inbox.








Click here to see more newsletters